Putting Science to Work

In the News

  • /Media/Default/images/infd.jpg
    Syngene enters pact with GSK to provide drug discovery services

    Money Control-27/03/2018. As part of the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas.

    .

  • /Media/Default/images/infd.jpg
    Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl

    Money Control-24/01/2018. With a focus on future business growth, the company has done lot of investments – building new infrastructure and capabilities and they are now ready, said Hunt...

    .

  • We are in the process of implementing a $200 million growth capex plan to expand capacity and extend capabilities

    Globally, we anticipate to see a healthy demand for high quality scientific services, not just in the pharma and biotechnology industries but also in other research focused industries...

    .

  • Bristol-Myers Squibb, Syngene International Expand Ongoing Research Collaboration

    Outook-14/11/2017. Syngene will set up a new dedicated facility spread across 25,000 sq. ft. of laboratory and office space for Bristol-Myers Squibb...

    .

  • Expect good momentum to continue in H2FY18: Syngene CEO

    Money Control-26/10/2017. The revenues for Syngene in the second quarter (July-September) were up 10.6 percent at Rs 334.2 crore versus Rs 303 crore for the...

    .

  • Syngene expands Amgen collaboration as it recovers from fire incident

    Outsourcing Pharma-31/07/2017. Syngene International is doubling the footprint of its research and development center....

  • Company on a path of recovery; Q1 has been solid: Manoj Nerurkar, Syngene International

    Economic Times-28/07/2017. Clearly we are on a recovery path, we believe we made a significant progress going from minus 6% to plus 6% in terms of revenue growth ...

  • Aim to get back to around 20% revenue growth in FY18: Syngene

    Money Control-28/04/2017. The tie-up with the Canadia Company is a good start for the biologics business...

  • Initiator Pharma selects Syngene and Research Toxicology Centre (RTC) as primary partners for the preclinical development of IPED2015.

    Cision News-19/04/2017. Initiator Pharma has selected Syngene, India and Research Toxicology Centre, Italy ( RTC) as contract research organizations (CROs) to conduct the pre-clinical development of the drug candidate IPED2015 for the treatment of ED.

  • Biologics and Biosimilars -Promising field for medicines for the future by Dr. Dhananjay Patankar (Head-Pharmaceutical and Biopharmaceutical Development)

    Pharma Focus Asia-09/03/2017. As per Make in India campaign by the government, Indian biotech industry, comprising bio pharmaceuticals, is expected to grow at a rate of 30 per cent a year and reach US$100 billion by 2025.

Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget